Physical Activity Program Implementation in Hospitalized Positive COVID-19 Older Adults (Cov-activity)

May 31, 2023 updated by: University Hospital, Toulouse

Feasibility and Effect of Implementing Physical Activity Program Implementation During COVID-19 in Hospitalized Positive COVID-19 Older Adults

Our hypothesis was that physical activity program will be acceptable and may counteract physical and mental decline among older adults hospitalized in COVID-19 unit

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The 30 second chair test, balance with joint-feet and semi-tandem stance, and 4 meters comfortable walking test were evaluated. Depending on their score, a specific physical activity (PA) program was selected and explained. The program was printed, explained and left in the room. This intervention included 5 different PA programs.

Final evaluation (one day before leaving the unit) recording physical performance (same physical tests used for inclusion evaluation), Hospital Anxiety and depression (HAD) score, Activities Daily Living (ADL) and self-satisfaction of the program.

Study Type

Observational

Enrollment (Actual)

62

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Grenoble, France
        • CHU de Grenoble
      • Toulouse, France, 31059
        • University Hospital toulouse
  • Guadeloupe
      • Pointe-à-Pitre, Guadeloupe
        • CHU Pointe-à-Pitre Abîmes - GUADELOUPE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

75 years and older (Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Included in a French COVID-19 geriatric unit in Toulouse, hospitalized for a positive COVID-19 infection

Description

Inclusion Criteria:

  • Patients aged 75 years and over
  • Hospitalized in a French COVID-19 geriatric unit
  • Positive COVID-19 infection made by Real-time Polymerase Chain Reaction COVID-19 or suspected on thoracic lesions on computerized tomography.

Exclusion Criteria:

  • Exclusion of patients of palliative care,
  • Severe dementia or Mini Mental State Examination (MMSE) [14] below 18/30
  • Acute COVID-19 complication.
  • Activities of Daily Living < 2/6

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
One single group study
Patients aged 75 years and over Hospitalized in a French COVID-19 geriatric unit Positive COVID-19 infection made by Real-time Polymerase Chain Reaction COVID-19 or suspected on thoracic lesions on computerized tomography.
Other: physical activity program
  • 30 second chair test,
  • balance with joint-feet and semi-tandem stance
  • 4 meters comfortable walking test were evaluated

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of adherence of the intervention
Time Frame: through study completion, an average of 15 days
adherence of the intervention evaluated by the number of completed exercise days compared to the number of total intervention days
through study completion, an average of 15 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of physical performances
Time Frame: through study completion, an average of 15 days
Comparison between inclusion and final physical performances measured by the 30-second chair test, balance with joint-feet, semi-tandem stance, 4 meters comfortable walking test, functional abilities with the evaluation of ADL score and HAD scores.
through study completion, an average of 15 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Toulouse

Investigators

  • Principal Investigator: Yves Rolland, MD, University Hospital, Toulouse

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2021

Primary Completion (Actual)

February 14, 2022

Study Completion (Actual)

February 14, 2022

Study Registration Dates

First Submitted

October 29, 2020

First Submitted That Met QC Criteria

November 27, 2020

First Posted (Actual)

December 1, 2020

Study Record Updates

Last Update Posted (Actual)

June 1, 2023

Last Update Submitted That Met QC Criteria

May 31, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC31/20/0145

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe